Compare Cytokinetics Inc (CYTK) vs Eni SpA (E) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Eni SpA — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Eni SpA trades at $56.1 (market cap $79.81B). The key difference: Eni SpA is far larger — about 9.3× Cytokinetics Inc's market cap, and Eni SpA pays a 4.39% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Eni SpA for 53 Days on average.
| CYTK | E | |
|---|---|---|
Market Cap | $8.62B | $79.81B |
Volume | 2,594,626 | 365,912 |
Sector | Health | Energy |
52-Week High | $87.26 | $57.61 |
52-Week Low | $54.76 | $34.03 |
Typical Hold Time | 19 Days | 53 Days |
Enterprise Value | $8.72B | $104.34B |
Dividend Yield | — | 4.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Eni (E) trades at $53.96, down 1.08% on the day, amid a bearish technical signal and mixed earnings performance. Revenue has declined from $132.5B in 2022 to $82.15B in 2025, though net income margin improved to 5.97%. Recent news highlights strategic moves in humanoid robotics, LNG projects, and fuel discounts. The stock shows attractive valuation with a P/E of 12.87 and P/S of 0.85, while cash flow remains positive but net cash flow turned negative in 2026 projections.
The outlook is cautious; low valuations and dividend payments offer value, but revenue declines and earnings misses pose risks. Analyst consensus is mixed with 34.62% buy ratings. Key risks include energy price volatility and execution of new tech initiatives. Further upside depends on stabilizing revenue and meeting earnings expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →
